Zoetis has announced that the licence for Cytopoint (lokivetmab) has been extended to include the treatment of pruritus associated with allergic dermatitis in dogs.

Cytopoint is an injectable monoclonal antibody therapy for dogs that targets and neutralises the cytokine IL-31, a mediator of allergic itch1.

Zoetis says the new claim was granted following a randomised, double-masked, multi-centred, placebo-controlled study which looked at Cytopoint’s efficacy and safety for the treatment of pruritus associated with allergic dermatitis in client-owned dogs. The study showed that Cytopoint significantly decreased pruritus, and improved skin lesions.2

Allison Henry, Product Manager Companion Animal Dermatology at Zoetis UK, says: "Allergic dermatitis is one of the most common skin conditions in dogs.3 The associated clinical signs – including scratching, hair loss and skin lesions – are disruptive for the dog, impacting their quality of life and that of its owner. Allergic skin disease is one of the most frequent reasons owners present their dog to a veterinarian.

"The licence extension demonstrates further innovation from Zoetis in the field of veterinary dermatology, and across the continuum of care, increasing the treatment options available to manage pruritus. Apoquel remains an ideal choice for short-term control due to its ability to provide rapid itch relief within four hours4 for as little as one day.5 This enables pruritus to be tightly controlled during the diagnostic work up,7 as well as being used for longer term control where tablets are the preferred method of administration.

"The sustained duration of action of Cytopoint makes it better suited to long-term management of pruritus, particularly when administering tablets is a challenge. Other benefits, such as no restrictions on age or with comorbidities, coupled with the flexibility of the new claim, make it a useful treatment at an earlier stage for more unique cases, e.g. young dogs or those with comorbidities."

For further information, contact your Zoetis Account Manager.

watch?v=A8EJ8LpLVzw&feature=youtu.be

References

  1. Gonzales AJ, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013; 24(1): 48−53. doi:10.1111/j.1365-3164.2012.01098.x
  2. Zoetis Study Report No C866C-XC-19-255.
  3. Hillier, A, Griffin, CE. The ACVD task force on canine atopic dermatitis (I): incidence and prevalence. Veterinary Immunology and Immunopathology 1999; 81: 147-151.
  4. Gadeyne C, et al. Efficacy of oclacitinib (APOQUEL®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014; 25(6): 512-8, e86. doi:10.1111/vde.12166.
  5. APOQUEL® Summary of Product Characteristics.
  6. Clear V, et al. Investigation of the effects of 30-day administration of oclacitinib (APOQUEL) on intradermal and allergen-specific IgE serology testing in atopic dogs. NAVDF proc, Nashville, TN.2015; p 32.
  7. Zoetis Market Research: Global APOQUEL CYTOPOINT Brand Health Tracker: Veterinarians: Wave 2 (2020)

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.